CN108368114B - 作为mnk抑制剂的吡咯并嘧啶化合物 - Google Patents

作为mnk抑制剂的吡咯并嘧啶化合物 Download PDF

Info

Publication number
CN108368114B
CN108368114B CN201680067666.6A CN201680067666A CN108368114B CN 108368114 B CN108368114 B CN 108368114B CN 201680067666 A CN201680067666 A CN 201680067666A CN 108368114 B CN108368114 B CN 108368114B
Authority
CN
China
Prior art keywords
tumors
agents
mmol
compound
mnk
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
CN201680067666.6A
Other languages
English (en)
Chinese (zh)
Other versions
CN108368114A (zh
Inventor
乔恩·詹姆斯·温特-霍尔特
爱德华·贾尔斯·麦基弗
史蒂芬·里维斯
乔安妮·奥萨波尼
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
LifeArc
Original Assignee
LifeArc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by LifeArc filed Critical LifeArc
Publication of CN108368114A publication Critical patent/CN108368114A/zh
Application granted granted Critical
Publication of CN108368114B publication Critical patent/CN108368114B/zh
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Immunology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Oncology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
CN201680067666.6A 2015-11-20 2016-11-16 作为mnk抑制剂的吡咯并嘧啶化合物 Expired - Fee Related CN108368114B (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GB1520499.3 2015-11-20
GBGB1520499.3A GB201520499D0 (en) 2015-11-20 2015-11-20 Compounds
PCT/GB2016/053579 WO2017085483A1 (en) 2015-11-20 2016-11-16 Pyrropyrimidine compounds as mnks inhibitors

Publications (2)

Publication Number Publication Date
CN108368114A CN108368114A (zh) 2018-08-03
CN108368114B true CN108368114B (zh) 2023-10-24

Family

ID=55133105

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201680067666.6A Expired - Fee Related CN108368114B (zh) 2015-11-20 2016-11-16 作为mnk抑制剂的吡咯并嘧啶化合物

Country Status (9)

Country Link
US (1) US10604524B2 (enExample)
EP (2) EP3377494B1 (enExample)
JP (1) JP6946290B2 (enExample)
CN (1) CN108368114B (enExample)
AU (1) AU2016355103B2 (enExample)
CA (1) CA3003554C (enExample)
ES (2) ES2872775T3 (enExample)
GB (1) GB201520499D0 (enExample)
WO (1) WO2017085483A1 (enExample)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI713455B (zh) 2014-06-25 2020-12-21 美商伊凡克特治療公司 ＭｎＫ抑制劑及其相關方法
PE20191349A1 (es) 2017-02-14 2019-09-30 Effector Therapeutics Inc Inhibidores de mnk sustituidos con piperidina y metodos relacionados con los mismos
CN109020957B (zh) * 2017-06-12 2023-01-13 南京天印健华医药科技有限公司 作为mnk抑制剂的杂环化合物
CA3117169A1 (en) 2018-10-24 2020-04-30 Effector Therapeutics, Inc. Crystalline forms of mnk inhibitors
CN110903286B (zh) * 2019-12-16 2021-09-24 沈阳药科大学 4,6-双取代吡啶[3,2-d]嘧啶类化合物及其制备和应用

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101511837A (zh) * 2006-07-10 2009-08-19 德维洛根股份公司 用于药物组合物的吡咯并嘧啶

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NZ207394A (en) 1983-03-08 1987-03-06 Commw Serum Lab Commission Detecting or determining sequence of amino acids
ES2203642T3 (es) * 1995-06-07 2004-04-16 Pfizer Inc. Derivados de pirimidina heterociclicos con anillos condensados.
IL129825A0 (en) 1996-11-27 2000-02-29 Pfizer Fused bicyclic pyrimidine derivatives
BR9916746A (pt) 1999-06-03 2005-01-11 Abbott Lab Compostos anti-inflamatórios que inibem adesão de célula
US20050153989A1 (en) 2004-01-13 2005-07-14 Ambit Biosciences Corporation Pyrrolopyrimidine derivatives and analogs and their use in the treatment and prevention of diseases
CA2572331A1 (en) 2004-07-02 2006-02-09 Exelixis, Inc. C-met modulators and method of use
TW200730527A (en) * 2005-12-02 2007-08-16 Takeda Pharmaceuticals Co Fused heterocyclic compound
WO2007115822A1 (en) * 2006-04-07 2007-10-18 Develogen Aktiengesellschaft Thienopyrimidines having mnkl /mnk2 inhibiting activity for pharmaceutical compositions
EP2219649A2 (en) * 2007-11-22 2010-08-25 Boehringer Ingelheim International Gmbh Use of mnk inhibitors for the treatment of alzheimer's disease
JP5626748B2 (ja) * 2008-07-02 2014-11-19 キッコーマン株式会社 ペプチド含有調味料
MX2012009735A (es) 2010-02-26 2012-09-12 Boehringer Ingelheim Int 4-[cicloalquiloxi (hetero) arilamino] tieno [2,3-d] pirimidinas que tienen actividad inhibitoria de mnk1/mnk2 para composiciones farmaceuticas.
EA201201192A1 (ru) 2010-02-26 2013-04-30 Бёрингер Ингельхайм Интернациональ Гмбх Тиенопиримидины, содержащие замещенную алкильную группу, предназначенные для фармацевтических композиций
HK1222173A1 (zh) 2013-02-01 2017-06-23 Bayer Pharma Aktiengesellschaft 取代的吡唑并嘧啶基氨基-吲唑类
EP2964656A1 (en) 2013-03-06 2016-01-13 Bayer Pharma Aktiengesellschaft Substituted thiazolopyrimidines
CN104744446B (zh) * 2013-12-30 2019-06-25 广东东阳光药业有限公司 杂芳化合物及其在药物中的应用

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101511837A (zh) * 2006-07-10 2009-08-19 德维洛根股份公司 用于药物组合物的吡咯并嘧啶

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
Novel Water-Soluble Substituted Pyrrolo[3,2-d]pyrimidines:Design, Synthesis, and Biological Evaluation as Antitubulin;Aleem Gangjee et al.;《PHARMACEUTICAL RESEARCH》;20120720;第29卷(第11期);第3033-3037页 *

Also Published As

Publication number Publication date
HK1253576A1 (en) 2019-06-21
AU2016355103B2 (en) 2021-07-08
EP3792264A1 (en) 2021-03-17
JP2018534316A (ja) 2018-11-22
CA3003554A1 (en) 2017-05-26
JP6946290B2 (ja) 2021-10-06
EP3377494B1 (en) 2021-03-03
GB201520499D0 (en) 2016-01-06
AU2016355103A1 (en) 2018-05-31
WO2017085483A1 (en) 2017-05-26
CN108368114A (zh) 2018-08-03
US20180346469A1 (en) 2018-12-06
ES2872775T3 (es) 2021-11-02
EP3377494A1 (en) 2018-09-26
ES2972862T3 (es) 2024-06-17
US10604524B2 (en) 2020-03-31
CA3003554C (en) 2023-08-29
EP3792264B1 (en) 2024-01-03

Similar Documents

Publication Publication Date Title
EP2403853B1 (en) Pyrrolopyrimidines used as kinase inhibitors
RU2487875C2 (ru) ПРОИЗВОДНЫЕ ИМИДАЗО [1,2-b]ПИРИДАЗИНА И ПИРАЗОЛО[1,5-a]ПИРИМИДИНА И ИХ ПРИМЕНЕНИЕ В КАЧЕСТВЕ ИНГИБИТОРА ПРОТЕИНКИНАЗ
CN101379060B (zh) 作为Aurora激酶抑制剂的苯并唑系衍生物、组合物和使用方法
CN100404540C (zh) 可抑制蛋白激酶的噻唑并、噁唑并和咪唑并喹唑啉化合物
CN108368114B (zh) 作为mnk抑制剂的吡咯并嘧啶化合物
JP7181647B2 (ja) Ｍｎｋ阻害剤としての縮合チアゾロピリミジン誘導体
CN110407839B (zh) 含杂芳基酰胺结构的三唑并杂环类化合物的制备及应用
HK40037886B (en) Pyrropyrimidine compounds as mnks inhibitors
HK40037886A (en) Pyrropyrimidine compounds as mnks inhibitors
HK1253576B (en) Pyrropyrimidine compounds as mnks inhibitors
HK40065647B (en) Fused thiazolopyrimidine derivatives as mnks inhibitors
HK40065647A (en) Fused thiazolopyrimidine derivatives as mnks inhibitors
Webb-Smith 2) Patent Application Publication o Pub. No.: US 2020/0247822 A1
HK1253575B (en) Fused thiazolopyrimidine derivatives as mnks inhibitors

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
GR01 Patent grant
GR01 Patent grant
CF01 Termination of patent right due to non-payment of annual fee

Granted publication date: 20231024

CF01 Termination of patent right due to non-payment of annual fee